J. Andrew Orr-Skirvin, PharmD, BCOP

Chair and Clinical Professor, Department of Pharmacy and Health Systems Sciences, Director of Pharmaceutical Industry Fellowship Program

Department of Pharmacy and Health Systems Sciences, School Leadership Team, School of Pharmacy and Pharmaceutical Sciences

Office: R218TF

Email: [email protected]

Phone: 617-373-4166

View Résumé/CV

Dr. Orr-Skirvin has been a faculty member for teaching pharmacy students and providing clinical services to oncology patients since 1996. Interest areas include supportive care for oncology patients including pain management, symptom control, minimizing toxicity, student engagement through active learning and promoting skill development for practice readiness. Dr. Orr-Skirvin has patient care experience with adult suffering from leukemias, lymphomas, lung cancer, pancreatic cancer, prostate cancer, breast cancer, esophageal & gastric cancer, head & neck cancer and many more. Dr. Orr-Skirvin is the director of the Pharmaceutical Industry Fellowship program at Northeastern University.

Education:

Oregon State University, Bachelor of Science in Pharmacy, 1992
University of Texas at Austin, Doctor of Pharmacy, 1995
Southwest Veterans Hospital, Audie Murphy Division, Oncology Specialty Pharmacy Residency 1995-1996.

Certification:

Board Certified Oncology Pharmacist 2000

Specializations:

Hematology/Oncology Pharmacy Practice

Research:

Supportive care
Pain Management
Adult Oncology
Palliative Care

Affiliations:

Dana Farber Cancer Institute

Publications:

McCormick M, Awo Osei-Anto H, Martinez RM, Editors; Committee on Addressing Sickle Cell Disease. National Academies of Sciences, Engineering, and Medicine 2020. Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action. Washington, DC: The National Academies Press. https://doi.org/10.17226/25632 .  

Fang K, Orr-Skirvin JA. Review of systemic lupus erythematosus, treatment, and future directions. US Pharm. 2019;44(8)(Specialty&Oncology suppl)3-7.  

Okwerekwu, I, Skirvin JA. Sickle Cell Disease Pain Management. US Pharm 2018;43(3)12-18.  

Leblebjian H, DeAngelo DJ, Skirvin JA, et. Al. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia Leuk Res. 2013 Jul;37(7):747-51.  

Douglass MA, Casale JP, Skirvin JA, Divall M. A Virtual Patient Software Program to Improve Pharmacy Student Learning in a Comprehensive Disease Management Course. A J Pharm Ed 2013:77;article 172. 

Selected Public Service:

AACP Academic Leadership Fellows Program (ALFP) program 2019-2020  
National Academies of Science, Engineering & Medicine 2019
Hematology/Oncology Pharmacy Association, Sub-committee on Leadership 2018-2022 

LinkedIn:

https://www.linkedin.com/in/andrewskirvin/